PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression

Background. This work focused on investigating the role of programmed death ligand 2 (PD-L2) in the progression of breast cancer by utilizing breast cancer specimens and cells. Materials and Methods. The serum levels of soluble PD-L2 (sPD-L2) in breast cancer patients and healthy individuals were an...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuling Sun, Jie Yang, Yachun Chen, Yundi Guo, Jian Xiong, Xuqin Guo, Yawen Zhang, Li Gu, Min Tong, Weipeng Wang, Jing Sun
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2024/3145695
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850209344269844480
author Yuling Sun
Jie Yang
Yachun Chen
Yundi Guo
Jian Xiong
Xuqin Guo
Yawen Zhang
Li Gu
Min Tong
Weipeng Wang
Jing Sun
author_facet Yuling Sun
Jie Yang
Yachun Chen
Yundi Guo
Jian Xiong
Xuqin Guo
Yawen Zhang
Li Gu
Min Tong
Weipeng Wang
Jing Sun
author_sort Yuling Sun
collection DOAJ
description Background. This work focused on investigating the role of programmed death ligand 2 (PD-L2) in the progression of breast cancer by utilizing breast cancer specimens and cells. Materials and Methods. The serum levels of soluble PD-L2 (sPD-L2) in breast cancer patients and healthy individuals were analyzed by means of the enzyme-linked immunosorbent assay, and the PD-L2 levels within 416 resected breast cancer specimens were assessed through immunohistochemistry. Concurrently, in vitro cell experiments and in vivo animal experiments were carried out to analyze the relationship between PD-L2 and the invasion and migration of breast cancer. Results. The concentration of sPD-L2 in breast cancer patients significantly increased compared to that in the control groups. Additionally, breast cancer patients with high concentrations of sPD-L2 had higher Ki67 values (≥30%) and tumor grades. PD-L2 was expressed in 79.09% of the cancer samples, which exhibited a positive correlation with the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). Furthermore, we discovered that knockdown of PD-L2 inhibited the migratory and invasive abilities of both MCF-7 and MDA-MB231 cells. Conclusion. Our findings demonstrated that knockdown of PD-L2 suppressed tumor growth, providing novel insights into important biological functions.
format Article
id doaj-art-91d6d2f69f7645258ad424fa17d1dc28
institution OA Journals
issn 2314-7156
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-91d6d2f69f7645258ad424fa17d1dc282025-08-20T02:10:02ZengWileyJournal of Immunology Research2314-71562024-01-01202410.1155/2024/3145695PD-L2 Expression in Breast Cancer Promotes Tumor Development and ProgressionYuling Sun0Jie Yang1Yachun Chen2Yundi Guo3Jian Xiong4Xuqin Guo5Yawen Zhang6Li Gu7Min Tong8Weipeng Wang9Jing Sun10Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyJiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyJiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyJiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyJiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyCenter for Drug Metabolism and PharmacokineticsCenter for Drug Metabolism and PharmacokineticsJiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyJiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyCenter for Drug Metabolism and PharmacokineticsJiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in OncologyBackground. This work focused on investigating the role of programmed death ligand 2 (PD-L2) in the progression of breast cancer by utilizing breast cancer specimens and cells. Materials and Methods. The serum levels of soluble PD-L2 (sPD-L2) in breast cancer patients and healthy individuals were analyzed by means of the enzyme-linked immunosorbent assay, and the PD-L2 levels within 416 resected breast cancer specimens were assessed through immunohistochemistry. Concurrently, in vitro cell experiments and in vivo animal experiments were carried out to analyze the relationship between PD-L2 and the invasion and migration of breast cancer. Results. The concentration of sPD-L2 in breast cancer patients significantly increased compared to that in the control groups. Additionally, breast cancer patients with high concentrations of sPD-L2 had higher Ki67 values (≥30%) and tumor grades. PD-L2 was expressed in 79.09% of the cancer samples, which exhibited a positive correlation with the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). Furthermore, we discovered that knockdown of PD-L2 inhibited the migratory and invasive abilities of both MCF-7 and MDA-MB231 cells. Conclusion. Our findings demonstrated that knockdown of PD-L2 suppressed tumor growth, providing novel insights into important biological functions.http://dx.doi.org/10.1155/2024/3145695
spellingShingle Yuling Sun
Jie Yang
Yachun Chen
Yundi Guo
Jian Xiong
Xuqin Guo
Yawen Zhang
Li Gu
Min Tong
Weipeng Wang
Jing Sun
PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression
Journal of Immunology Research
title PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression
title_full PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression
title_fullStr PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression
title_full_unstemmed PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression
title_short PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression
title_sort pd l2 expression in breast cancer promotes tumor development and progression
url http://dx.doi.org/10.1155/2024/3145695
work_keys_str_mv AT yulingsun pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT jieyang pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT yachunchen pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT yundiguo pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT jianxiong pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT xuqinguo pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT yawenzhang pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT ligu pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT mintong pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT weipengwang pdl2expressioninbreastcancerpromotestumordevelopmentandprogression
AT jingsun pdl2expressioninbreastcancerpromotestumordevelopmentandprogression